Leerink Partnrs Issues Optimistic Outlook for RARE Earnings

Key Points

• Analysts at Leerink Partners have increased their Q3 2025 earnings per share estimate for Ultragenyx Pharmaceutical to ($1.31), up from the previous estimate of ($1.39).
• Ultragenyx's stock has a current market cap of $2.63 billion, with shares opening at $27.83, down 0.8% recently.
• There is a general consensus among analysts with a "Moderate Buy" average rating and a price target of $82.17 for Ultragenyx shares, despite some firms reducing their target prices.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) - Leerink Partnrs boosted their Q3 2025 EPS estimates for shares of Ultragenyx Pharmaceutical in a research note issued to investors on Tuesday, August 5th. Leerink Partnrs analyst J. Schwartz now forecasts that the biopharmaceutical company will earn ($1.31) per share for the quarter, up from their previous estimate of ($1.39). The consensus estimate for Ultragenyx Pharmaceutical's current full-year earnings is ($5.18) per share. Leerink Partnrs also issued estimates for Ultragenyx Pharmaceutical's Q4 2025 earnings at ($1.15) EPS, FY2025 earnings at ($5.20) EPS and FY2026 earnings at ($4.58) EPS.

RARE has been the subject of a number of other reports. Wedbush reduced their target price on shares of Ultragenyx Pharmaceutical from $35.00 to $34.00 and set a "neutral" rating for the company in a research note on Monday, July 14th. Morgan Stanley reduced their target price on shares of Ultragenyx Pharmaceutical from $65.00 to $55.00 and set an "overweight" rating for the company in a research note on Monday, July 14th. William Blair initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 target price for the company. Canaccord Genuity Group reduced their target price on shares of Ultragenyx Pharmaceutical from $136.00 to $128.00 and set a "buy" rating for the company in a research note on Friday. Finally, Cantor Fitzgerald decreased their price objective on shares of Ultragenyx Pharmaceutical from $112.00 to $105.00 and set an "overweight" rating for the company in a report on Wednesday, August 6th. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $81.50.

Ultragenyx Pharmaceutical Trading Up 1.4%

NASDAQ RARE traded up $0.39 during trading on Friday, reaching $27.78. The company's stock had a trading volume of 550,629 shares, compared to its average volume of 1,291,107. The stock has a market capitalization of $2.68 billion, a PE ratio of -5.02 and a beta of 0.25. The business has a 50-day moving average price of $33.15 and a 200-day moving average price of $36.56. Ultragenyx Pharmaceutical has a 1-year low of $25.81 and a 1-year high of $60.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.10. The firm had revenue of $166.50 million for the quarter, compared to analyst estimates of $161.37 million. Ultragenyx Pharmaceutical had a negative net margin of 87.34% and a negative return on equity of 237.48%. The company's revenue for the quarter was up 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.52) EPS.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

A number of institutional investors and hedge funds have recently bought and sold shares of RARE. Aster Capital Management DIFC Ltd bought a new position in Ultragenyx Pharmaceutical during the fourth quarter worth $35,000. Invesco Ltd. increased its holdings in Ultragenyx Pharmaceutical by 1.5% in the 4th quarter. Invesco Ltd. now owns 1,699,756 shares of the biopharmaceutical company's stock valued at $71,509,000 after buying an additional 25,487 shares during the period. Renaissance Technologies LLC lifted its holdings in shares of Ultragenyx Pharmaceutical by 39.9% during the 4th quarter. Renaissance Technologies LLC now owns 254,700 shares of the biopharmaceutical company's stock worth $10,715,000 after acquiring an additional 72,600 shares during the period. Raymond James Financial Inc. bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $916,000. Finally, F M Investments LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth about $1,767,000. Institutional investors own 97.67% of the company's stock.

Insider Transactions at Ultragenyx Pharmaceutical

In related news, Director Corazon (Corsee) D. Sanders sold 2,405 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $37.39, for a total transaction of $89,922.95. Following the transaction, the director owned 15,344 shares of the company's stock, valued at approximately $573,712.16. The trade was a 13.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 5.50% of the company's stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.